Safety and Effects of Ramipril Combined With Candesartan

Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00356395

Enrollment

Registered

2006-07-26

Start date

2003-08-31

Completion date

2006-03-31

Last updated

2006-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

endothelial function, insulin resistance, adipocytokines

Brief summary

we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.

Detailed description

Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).

Interventions

DRUGramipril, candesartan

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

35 Years to 75 Years

Healthy volunteers

Inclusion criteria

* patients with mild to moderate hypertension

Exclusion criteria

* We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.

Design outcomes

Primary

Measure	Time frame
comparison of endothelium-dependent dilation among the 3 treatment schemes	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026